GLOBIPHARM
ActiveSummary
GLOBIPHARM has been active since 2012 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €90,837 and a net result of €16,399. Equity is growing by about 103% per year across the filed financial years. Its solvency ranks better than 32% of 13,639 sector peers (NACE 46, financial year 2025). The computed 12-month bankruptcy probability is 0.2% (very low).
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
09-04
NBB filing
Annual accounts filed
financial year 2025 · micro format
2025
30-04
NBB filing
Annual accounts filed
financial year 2024 · micro format
2024
03-04
NBB filing
Annual accounts filed
financial year 2023 · micro format
2023
31-03
NBB filing
Annual accounts filed
financial year 2022 · micro format
2022
25-04
NBB filing
Annual accounts filed
financial year 2021 · micro format
2021
30-09
Financial
Highest result from 2019 to 2025net €46,346 ▲3,900%
Operating result €71,790, net result €46,346, both a record.
29-03
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format
2020
30-09
Financial
Weakest financial yearnet €1,159 ▼92.1%
Net result drops to €1,159, the lowest in the series; recovery starts the following year.
26-03
NBB filing
Annual accounts filed
financial year 2019 · micro format
2019
25-04
NBB filing
Annual accounts filed
financial year 2018 · micro format
2018
29-03
NBB filing
Annual accounts filed
financial year 2017 · micro format
2017
26-04
NBB filing
Annual accounts filed
financial year 2016 · abbreviated format
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.Of the 13 annual accounts filed, the latest 10 are here; all 13 are under Financials.
0 of 4 deeds read
About the unread acts
We know of 4 Belgian Official Gazette acts for this company. None of them has been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.